Jancárková N, Zikán M, Pohlreich P, Freitag P, Matous B, Zivný J
Gynek.-porod. klinika 1. LF UK a VFN, Praha.
Ceska Gynekol. 2003 Jan;68(1):11-6.
The article presents a review of basic information on incidence and detection of BRCA 1 and BRCA 2 genes mutations. Results of investigation in a group of women with ovarian and breast cancer are presented.
Retrospective clinical-laboratory study and review.
Department of Gynaecology and Obstetrics, 1st Medical Faculty of Charles University, Prague, Apolinárská 18, Czech Republic.
Investigated group consisted of 16 persons--12 patients with ovarian or breast cancer and 4 healthy relatives of a woman--breast cancer patient and a carrier of BRCA 1 gene mutation. Protein truncation test (PTT) was performed in order to detect BRCA 1 gene mutation. This test detects mutations leading to premature termination of protein synthesis. Truncated proteins are easily discriminated from full size.
Three BRCA 1 gene alterations were identified in the investigated group of women suffering from ovarian or breast cancer. One asymptomatic person--carrier of BRCA 1 gene mutation--was identified in this study. She was daughter of a woman, a carrier of BRCA 1 gene mutation, with early onset of breast cancer and positive family history.
BRCA 1 and BRCA 2 gene mutations are of particular importance in the increasing risk of ovarian cancer and early onset of breast cancer as well as some other malignancies. Genetic testing and counselling including investigation of some other genetic and environmental factors, related to cancer risk, may be of clinical significance in patients with increased risk of certain malignancies.
本文综述了BRCA 1和BRCA 2基因突变的发生率及检测的基本信息。文中呈现了一组卵巢癌和乳腺癌女性患者的调查结果。
回顾性临床实验室研究及综述。
捷克共和国布拉格查理大学第一医学院妇产科,阿波利纳尔斯卡街18号。
研究组由16人组成——12例卵巢癌或乳腺癌患者以及4名健康亲属,其中一名女性乳腺癌患者是BRCA 1基因突变携带者。为检测BRCA 1基因突变进行了蛋白质截短试验(PTT)。该试验可检测导致蛋白质合成提前终止的突变。截短的蛋白质很容易与全长蛋白质区分开来。
在接受调查的卵巢癌或乳腺癌女性组中鉴定出3处BRCA 1基因改变。本研究中鉴定出一名无症状个体——BRCA 1基因突变携带者。她是一名BRCA 1基因突变携带者女性的女儿,其母亲乳腺癌发病早且有阳性家族史。
BRCA 1和BRCA 2基因突变在卵巢癌风险增加、乳腺癌早发以及其他一些恶性肿瘤中具有特别重要的意义。基因检测和咨询,包括对一些其他与癌症风险相关的遗传和环境因素的调查,对于某些恶性肿瘤风险增加的患者可能具有临床意义。